NLRP3 and Other metabolic disease: To determine whether KA ameliorates metabolic disorders by inhibiting the activation of the NLRP3 inflammasome, we fed mice a high-fat diet (HFD) with or without KA supplementation for 14 weeks and then performed a glucose tolerance test (GTT) and insulin tolerance test (ITT).